2022年4月1日 · Guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (HFrEF) now includes 4 medication classes that include sodium-glucose cotransporter-2 inhibitors (SGLT2i).

2024年8月4日 · If you have heart failure, you need beta-blockers -- even if you do not have symptoms. Beta-blockers are prescribed for patients with systolic heart failure and improve survival, even in people...

2024年2月12日 · Beta blockers are the mainstay heart failure treatment for patients with an LVEF of up to 40%, as seen in HFrEF. 2 High-quality evidence from multiple RCTs indicates that beta blockers can boost clinical status by improving left ventricular function and reducing symptoms of heart failure, and the risk of hospitalization and mortality. 2 In ...

Recent studies have shown that beta blocker therapy improves survival and reduces hospitalizations in patients who have chronic heart failure and left ventricular systolic...

2003年4月1日 · There is now conclusive evidence that β-blockers, when added to ACE inhibitors, substantially reduce mortality, decrease sudden death, and improve symptoms in patients with HF.

2024年8月7日 · Beta-blockers are one of the most widely prescribed classes of drugs to treat hypertension (high blood pressure) and are a mainstay treatment of congestive heart failure. Beta-blockers work...

2023年8月22日 · Beta-blockers are indicated and have FDA approval for the treatment of tachycardia, hypertension, myocardial infarction, congestive heart failure, cardiac arrhythmias, coronary artery disease, hyperthyroidism, essential tremor, aortic dissection, portal hypertension, glaucoma, migraine prophylaxis, and other conditions.

Beta-adrenergic receptor blockers play an important role in the management of cardiovascular disease, including hypertension, ischemic heart disease and chronic heart failure. They differ, though, in beta-selectivity, vasodilation properties, and other ancillary features.

Early blockade of this pathway with beta-blocker (BB) therapy is recommended as the first-line medication for patients with HF and reduced ejection fraction (HFrEF). Conversely, in patients with severe acute HF (AHF), including those with resolved cardiogenic shock (CS), BB initiation can be hazardous.

2005年10月18日 · Angiotensin-converting enzyme (ACE) inhibitors and β-blockers are potent therapies in heart failure. They lower total mortality and heart failure hospitalizations by 25% to 40% across all ages, functional capacities, degrees of left ventricular dysfunction, and causes. 1,2 But does it matter which intervention is given first?